Such features include MHC status and PD-L1/2 expression on cancer cells, total mutational and neoantigen burden, ascites composition, hot versus cold immune landscape, and the contribution of tumor stroma (cancer-associated fibroblasts) to tumor immunosuppression. This evidence concerns the gene HLA-C and cancer.